MARKET

HZNP

HZNP

Horizon Therapeutics Pub L
NASDAQ

Real-time Quotes | Nasdaq Last Sale

88.03
+0.65
+0.74%
Closed 16:47 05/24 EDT
OPEN
87.44
PREV CLOSE
87.38
HIGH
89.45
LOW
87.12
VOLUME
1.79M
TURNOVER
--
52 WEEK HIGH
120.54
52 WEEK LOW
82.51
MARKET CAP
20.24B
P/E (TTM)
24.11
1D
5D
1M
3M
1Y
5Y
Horizon Therapeutics plc to Present MIRROR Randomized Controlled Trial Primary Endpoint Data at The EULAR 2022 European Congress of Rheumatology
DUBLIN, May 24, 2022--Horizon Therapeutics plc (Nasdaq: HZNP) today announced a series of data presentations during The EULAR 2022 European Congress of Rheumatology, June 1 – 4 in Copenhagen.
Business Wire · 21h ago
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
 
Benzinga · 1d ago
4 Analysts Have This to Say About Horizon Therapeutics
Horizon Therapeutics (NASDAQ:HZNP) has observed the following analyst ratings within the last quarter:
Benzinga · 1d ago
SVB Securities Initiates Horizon Therapeutics at Market Perform With $95 Price Target
MT Newswires · 2d ago
Horizon Therapeutics Earnings Perspective: Return On Capital Employed
According to Benzinga Pro, during Q1, Horizon Therapeutics (NASDAQ:HZNP) earned $204.26 million, a 17.95% increase from the preceding quarter. Horizon Therapeutics's sales decreased to $885.25 million, a 12.7% change since Q4.
Benzinga · 5d ago
Paulson & Co. adds Agnico Eagle Mines, slashes stake in BP, expands position in Bausch Health
John Paulson's fund, Paulson & Co. reported its 13F filing for Q2 wherein it added Agnico Eagle Mines (AEM) with 10.3M shares and SPDR Gold Trust ETF (GLD) with 10M
Seekingalpha · 05/17 13:34
Horizon Therapeutics Begins Patient Enrolment in Phase 2 trial of Daxdilimab (HZN-7734) for Alopecia Areata
Horizon Therapeutics plc (NASDAQ: HZNP) enrolled first patient in a Phase 2, open-label, proof-of-concept trial of its drug candidate Daxdilimab (HZN-7734) to treat people with moderate-to-severe alopecia areata. The company is planning to enrol approximat...
Benzinga · 05/17 13:27
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (HZN-7734) for the Treatment of Alopecia Areata
DUBLIN, May 17, 2022--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2, open-label, proof-of-concept trial to evaluate its development-stage medicine daxdilimab (HZN-7734), a potentially first-in-class, fu...
Business Wire · 05/17 12:00
More
No Data
Learn about the latest financial forecast of HZNP. Analyze the recent business situations of Horizon Therapeutics Pub L through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

38.46%Strong Buy
61.54%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average HZNP stock price target is 140.73 with a high estimate of 162.00 and a low estimate of 122.50.
High162.00
Average140.73
Low122.50
Current 88.03
EPS
Actual
Estimate
0.440.881.311.75
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 746
Institutional Holdings: 242.75M
% Owned: 105.60%
Shares Outstanding: 229.88M
TypeInstitutionsShares
Increased
243
12.38M
New
87
9.87M
Decreased
209
15.12M
Sold Out
68
4.60M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.78%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Chairman/President/Chief Executive Officer/Director
Timothy Walbert
Chief Financial Officer/Executive Vice President
Aaron Cox
Executive Vice President/General Counsel
Sean Clayton
Executive Vice President
Michael DesJardin
Executive Vice President
Vikram Karnani
Executive Vice President
Andy Pasternak
Executive Vice President
Jeffrey Sherman
Executive Vice President
Elizabeth Thompson
Lead Director/Independent Director
Michael Grey
Independent Director
William Daniel
Independent Director
Jeffrey Himawan
Independent Director
Susan Mahony
Independent Director
Gino Santini
Independent Director
James Shannon
Independent Director
H. Thomas Watkins
Independent Director
Pascale Witz
No Data
No Data
About HZNP
Horizon Therapeutics plc is a biotechnology company that is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare, autoimmune and serious inflammatory diseases. The Company's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology and inflammation. The Company has two reportable segments: the orphan and the inflammation segment. The orphan segment includes the medicines TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, UPLIZNA and also the Company’s research and development (R&D) programs. TEPEZZA is a monoclonal antibody and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). KRYSTEXXA is an infused medicine for uncontrolled gout. The Company's other orphan segment medicines, RAVICTI, PROCYSBI and ACTIMMUNE, treats serious chronic diseases. The inflammation segment includes PENNSAID 2%, DUEXIS, RAYOS and VIMOVO medicines.

Webull offers kinds of Horizon Therapeutics PLC stock information, including NASDAQ:HZNP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HZNP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HZNP stock methods without spending real money on the virtual paper trading platform.